From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry has grown in recent years and by 2014 state bioscience firms employed just over 24,000 in nearly 1,300 business establishments. Four of the state’s five bioscience subsectors have contributed to its 2 percent overall employment gain since 2012, led by double-digit job growth in medical devices (up 11 percent). State academic institutions accounted for nearly $400 million in bioscience-related R&D expenditures in 2014 and NIH funding to these and other non-academic institutions totaled $150.6 million in 2015. Arizona inventors have had 1,751 patents issued in bioscience-related classes since 2012, primarily in medical and surgical devices but also in drugs and pharmaceuticals, microbiology and genetics, and in biochemistry. The state has seen a strong increase in venture capital invested in bioscience-related companies in recent years. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017
On March 27, 2017, Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive Officer (“CEO”) and be appointed to the Company’s Board of Directors.
WASHINGTON, D.C. – On March 22, 2017, Congresswoman Kyrsten Sinema (AZ-09) and Congressman Trey Hollingsworth (IN-09) introduced the Fostering Innovation Act, bipartisan legislation to provide commonsense regulatory relief for companies on the cutting edge of scientific and medical research.
On March 23, 2017, Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or the “Company”) announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act. On July 1, 2016, the Food and Drug Administration (“FDA”) approved the […]
- Science Exposed: Bringing Science to Life through the Arts
- SBIR Road Tour - Phoenix
- 2017 BIO International Convention
- 06/19/2017 - 06/22/2017
- San Diego
- RESI San Diego
- San Diego
- Opal Medical Devices Summit
- 06/26/2017 - 06/27/2017